<DOC>
	<DOC>NCT00415155</DOC>
	<brief_summary>The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.</brief_summary>
	<brief_title>A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Diagnosed with hepatocellular cancer Discontinued all previous therapies At least 18 years of age Have other treatment options that are potentially curative or effectivesuch as surgical resection, liver transplant or percutaneous ablation, and/or transcatheter arterial embolization. Transplanted liver HIV positive More than 2 previous systemic chemotherapy treatments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
</DOC>